Showing results (31-40 of 80) with videos related to
Sort By:
Pageof 8
Haematologica|July 11, 2020
DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switchMichaela Novakova, Marketa Zaliova, Karel Fiser, et al.Journal of Immunological Methods|April 3, 2017
Lot-to-lot stability of antibody reagents for flow cytometrySebastian Böttcher, Vincent H J van der Velden, Neus Villamor, et al.British Journal of Haematology|February 27, 2016
Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemiaCristina López, Anke K Bergmann, Ulrike Paul, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trialSebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.Frontiers in Oncology|February 2, 2023
Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemiaAnke Schilhabel, Monika Szczepanowski, Ellen J van Gastel-Mol, et al.Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.Leukemia|August 16, 2022
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trialHeiner Zimmermann, Christian Koenecke, Martin H Dreyling, et al.Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.Pageof 8